Track topics on Twitter Track topics that are important to you
Roche announced two clinical trial wins notably, its Tecentriq immunotherapy made advances against lung cancer when mixed with other treatments.
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017. The event will bring together leading expert allergists to discuss the emerging treatment landscape in peanut allergy. Topics...
With positive results from a closely watched clinical trial announced Monday, Roche (RHHBY) is on the cusp of joining Merck (MRK) in owning an immunotherapy combination proven effective for patients…
Watch the LIVE WEBCAST starting at 1 pm, Eastern, Saturday, November 18, 2017 in partnership with Georgetown University Hospital, GRACE presents: 2017 Advances in Immunotherapy: What Lung Cancer Patients Need to KnowRelated Posts:
Peanut Allergy Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy Pipeline Review, H2 2017, provides an overview of the Peanut Allergy Immunology pipeline landscape.Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mi...
National Harbor, MD: It’s time for the first of our Gems from the Poster Halls following the Society for Immunotherapy…
Agreement Focuses on Development of Next-Generation Biologics to Selectively Modulate T Cell Activity for the Treatment of Autoimmune Diseases Cue Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engin
John KingAlthough providing immunizations is still a relatively new service line for the pharmacy, it is one that has grown rapidly in just a few short years — influenza vaccinations administered at pharmacies increased by more than 500% over a six-year time period. Yet, overall adult immunization rates in the United States remained relatively stagnant.
Michael JohnsenResearchers at the Influenza Center in Bergen, Norway recently concluded that annual influenza vaccination does not increase susceptibility to influenza infection in years of vaccine mismatch. read more
MSI Diagnostic Testing Available for Precision Cancer Immunotherapy CIRCULOGENE, a leading liquid biopsy company advancing precision medicine through personalized molecular genetics testing, has announced the availability of microsatellite instability (MSI) biomarker testing for multiple cancer types. The advanced immunotherapy testing is
PIN Pharma today announced the initiation of a Phase 1 clinical trial for its novel immune-modulator, PIN-2. This first-in-human, proof-of-concept study is being conducted in oncology patients with solid tumors by PIN Pharma’s wholly owned Australian subsidiary, PIN Pharma Pty Ltd. The study is designed to show changes in the human immune system...
Research in the AAAAI’s journal, The Journal of Allergy and Clinical Immunology (JACI), is giving new insight into the atopic march and what conditions may indicate a higher risk of further allergic disease. MILWAUKEE (PRWEB) November 15, 2017 New research in the AAAAI’s journal, The Journal of Allergy and Clinical Immunology (JACI), is giving insight into how allergic disease typically progr...
CHICAGO, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, along with Georgetown Lombardi Comprehensive Cancer Center, in Washington, D.C., and John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center announce a new rese...
Press Release Montrouge, France, November 14, 2017 DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association Primary endpoint of Phase IIb study was met after 12 months of treatment Long-term extension data showed treatment benefit increases over time Ongoi...
-- ARCH Venture Partners joins Vatera Healthcare Partners as Equity Investor -- -- Proceeds Will Support Phase II Study of Nexvax2®, ImmusanT’s Immunotherapy and Diagnostic for Celiac Disease -- -- Steven Gillis, Ph.D., and Thomas Daniel, M.D. join Board of Directors --
SnapshotVaccines are products designed to trigger protective immune responses and prepare the immune system to fight future infections from diseasecausing agents. Vaccines stimulate the immune system's production of antibodies that identify and destroy diseasecausing organisms that enter the body. Vaccines provide immunity against one or several diseases that can lessen the severity or prevent cer...
MD Anderson is collaborating with the Parker Institute for Cancer Immunotherapy and Seres Therapeutics to develop a cancer-targeting bacterial cocktail.
Tusk Therapeutics is working on immunotherapies to ignite the immune system against cancer. The £2.5M grant will help it to accelerate their development. Tusk Therapeutics focuses on immuno-oncology to ‘harness the power’ of the immune system. One of its candidates ... This awesome article British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy appeared first on Labiotech.eu...
A recent study shows that there are no negative effects from having annual influenza vaccination
The wind-down of the Global Polio Eradication Initiative means the end of the $1 billion a year it funnels into the WHO as well as immunization efforts.
Presentation to Examine the Potential of LAMP Enhancing Antitumor Immunity Tomorrow, Immunomic Therapeutics, Inc. scientist, Dr. Pratima Sinha, will present at the 3rd Annual International Conference on Vaccine Research and Development. Dr. Sinha will discuss her research employing LAMP technology in hopes of enhancing antitumor immunity. Specif...
Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but perhaps not to the level of expectation for a company ... This awesome article Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma appeared fi...
A team has engineered two stem cell lines into 'synthetic T cells' that destroy breast cancer cells in vitro.
Immunotherapy – A big word with much meaning. There’s no use in talking about their history. The fact that immunotherapies seem to be the next big thing in biotech is reason enough to discuss them. For this purpose, we have ... This awesome article Top 5 Things to Know About Immunotherapies – A Review appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)
The initial results were presented at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting.